Patrick Schöffski

iOnctura to present research at leading scientific conferences in June 2023

Retrieved on: 
Thursday, June 1, 2023
European Hematology Association, Research, ASCO, Congress, Patrick Schöffski, American Society of Clinical Oncology, CEST, EHA, Annual general meeting, Society, Pharmaceutical industry

GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

Key Points: 
  • GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.
  • The iOnctura team will present the Company's research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.
  • American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
    European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany
    European Association for Cancer Research (EACR) Congress 2023, Torino, Italy
    Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

iOnctura to present research at leading scientific conferences in June 2023

Retrieved on: 
Thursday, June 1, 2023
European Hematology Association, Research, ASCO, Congress, Patrick Schöffski, American Society of Clinical Oncology, CEST, EHA, Annual general meeting, Society, Pharmaceutical industry

GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

Key Points: 
  • GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.
  • The iOnctura team will present the Company's research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.
  • American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
    European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany
    European Association for Cancer Research (EACR) Congress 2023, Torino, Italy
    Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

Retrieved on: 
Monday, February 1, 2021
Anatomical pathology, Sarcoma, Soft-tissue sarcoma, Clinical medicine, Health, Epidemiology, Patrick Schöffski

HOUSTON, Feb. 1, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has signed an agreement with Catalyst Clinical Research (Catalyst), a contract research organization, to manage its US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs.

Key Points: 
  • HOUSTON, Feb. 1, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has signed an agreement with Catalyst Clinical Research (Catalyst), a contract research organization, to manage its US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs.
  • Soft tissue sarcomas are the most common form of sarcoma, accounting for an estimated 130,000 incident cases per year worldwide.
  • "Catalyst Oncology is thrilled to be the selected partner to collaborate with Moleculin on this potentially ground-breaking study."
  • Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry through two established solutions: Catalyst Flex and Catalyst Oncology.

Genetron Health to Highlight Data from 18 Studies at ESMO 2020

Retrieved on: 
Friday, September 18, 2020
Translational medicine, Precision medicine, ESMO, Oncology, European Society for Medical Oncology, Branches of biology, Patrick Schöffski

The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development.

Key Points: 
  • The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development.
  • Data that will be highlighted at the ESMO Virtual Congress were generated in collaboration with more than 10 notable cancer centers and clinical hospitals in China.
  • These studies aim at gathering specific data for the Chinese population in order to design precision oncology therapies for the domestic market.
  • We are pleased to showcase our data from 18 research studies at the upcoming ESMO Virtual Congress.

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Retrieved on: 
Friday, November 22, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Monoclonal antibodies, Drugs, Clinical medicine, Medicine, Novimmune, Patrick Schöffski, the Phase 1 Clinical Trial, ZW25

The promising ZW25 data at ESMO Asia further build momentum for the expanding footprint of our ZW25 clinical development program with BeiGene, said Ali Tehrani, Ph.D., President and CEO of Zymeworks.

Key Points: 
  • The promising ZW25 data at ESMO Asia further build momentum for the expanding footprint of our ZW25 clinical development program with BeiGene, said Ali Tehrani, Ph.D., President and CEO of Zymeworks.
  • The updated single agent results of the ongoing Phase 1 trial of ZW25 in patients with HER2expressing solid tumors include additional safety and anti-tumor activity data from those presented at the ESMO 2019 Congress.
  • ZW25 is being evaluated in Phase 1 and Phase 2 clinical trials across North America and South Korea.
  • Zymeworks lead clinical candidate, ZW25, is a novel Azymetric bispecific antibody currently in Phase 2 clinical development.

Global Soft Tissue Sarcoma Clinical Trial Pipeline Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 4, 2019
Health, Clinical trials, Oncology, Pharmaceutical, Health, Sarcoma, Clinical medicine, Medicine, Soft-tissue sarcoma, Clinical trial, SARC, Draft:Robert Maki, Patrick Schöffski

The "Global Soft Tissue Sarcoma Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Soft Tissue Sarcoma Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Soft Tissue Sarcoma Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Soft Tissue Sarcoma market.
  • It covers emerging therapies for Soft Tissue Sarcoma in active clinical development stages including early and late stage clinical trials.
  • The report provides Soft Tissue Sarcoma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

Retrieved on: 
Thursday, May 30, 2019
Asco, American Society of Clinical Oncology, Patrick Schöffski

ASCO is the largest annual gathering of medical professionals in oncology, held every year at the beginning of June in Chicago.

Key Points: 
  • ASCO is the largest annual gathering of medical professionals in oncology, held every year at the beginning of June in Chicago.
  • Dr Bosch's presentation will provide updates about the Company's DCVax-Direct and DCVax-L programs.
  • The DCVax-Direct updates will include follow-up data from the Company's Phase I trial for all types of inoperable solid tumors, and plans for further trials.
  • The industry theater presentation will not be an official presentation of the 2019 ASCO Annual Meeting.

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

Retrieved on: 
Monday, November 5, 2018
Vaccination, Vaccine, Virology, Patrick Schöffski

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.

Key Points: 
  • Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
  • John is an accomplished executive leader with more than 25 years' experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries.
  • Alfredo Nicosia, Chief Executive Officer of Nouscom, said: "As a respected executive leader, John is an outstanding addition to the Nouscom Board.
  • John McDonald commented on his appointment: "I'm excited to join the Nouscom Board at a pivotal time in the clinical development of Nouscom's oncology vaccine candidates.